183 related articles for article (PubMed ID: 31701281)
1. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.
Yamasaki F; Takano M; Yonezawa U; Taguchi A; Kolakshyapati M; Okumichi H; Kiuchi Y; Kurisu K
Childs Nerv Syst; 2020 Mar; 36(3):635-639. PubMed ID: 31701281
[TBL] [Abstract][Full Text] [Related]
2. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.
Avery RA; Hwang EI; Jakacki RI; Packer RJ
JAMA Ophthalmol; 2014 Jan; 132(1):111-4. PubMed ID: 24232489
[TBL] [Abstract][Full Text] [Related]
3. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
[TBL] [Abstract][Full Text] [Related]
4. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
5. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
6. Visual outcome following chemotherapy for progressive optic pathway gliomas.
Shofty B; Ben-Sira L; Freedman S; Yalon M; Dvir R; Weintraub M; Toledano H; Constantini S; Kesler A
Pediatr Blood Cancer; 2011 Sep; 57(3):481-5. PubMed ID: 21241008
[TBL] [Abstract][Full Text] [Related]
7. Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.
Pilotto C; Beshlawi I; Thomas A; Grundy RG
Childs Nerv Syst; 2018 Apr; 34(4):781-785. PubMed ID: 29249070
[TBL] [Abstract][Full Text] [Related]
8. Isolated optic nerve gliomas: a multicenter historical cohort study.
Shofty B; Ben-Sira L; Kesler A; Jallo G; Groves ML; Iyer RR; Lassaletta A; Tabori U; Bouffet E; Thomale UW; Hernáiz Driever P; Constantini S;
J Neurosurg Pediatr; 2017 Dec; 20(6):549-555. PubMed ID: 28984541
[TBL] [Abstract][Full Text] [Related]
9. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.
Avery RA; Mansoor A; Idrees R; Trimboli-Heidler C; Ishikawa H; Packer RJ; Linguraru MG
Neurology; 2016 Dec; 87(23):2403-2407. PubMed ID: 27815398
[TBL] [Abstract][Full Text] [Related]
10. Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study.
Heidary G; Fisher MJ; Liu GT; Ferner RE; Gutmann DH; Listernick RH; Kapur K; Loguidice M; Ardern-Holmes SL; Avery RA; Hammond C; Hoffman RO; Hummel TR; Kuo A; Reginald A; Ullrich NJ
J AAPOS; 2020 Dec; 24(6):349.e1-349.e5. PubMed ID: 33221469
[TBL] [Abstract][Full Text] [Related]
11. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
12. Optic pathway glioma in children: 10 years of experience in a single institution.
Doganis D; Pourtsidis A; Tsakiris K; Baka M; Kouri A; Bouhoutsou D; Varvoutsi M; Servitzoglou M; Dana H; Kosmidis H
Pediatr Hematol Oncol; 2016 Mar; 33(2):102-8. PubMed ID: 27007263
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
Thiagalingam S; Flaherty M; Billson F; North K
Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
[TBL] [Abstract][Full Text] [Related]
14. Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
Kilian A; Aigner A; Simon M; Salchow DJ; Potratz C; Thomale UW; Hernáiz Driever P; Tietze A
J Neurooncol; 2022 Feb; 156(3):589-597. PubMed ID: 34994964
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1.
Kuenzle C; Weissert M; Roulet E; Bode H; Schefer S; Huisman T; Landau K; Boltshauser E
Neuropediatrics; 1994 Dec; 25(6):295-300. PubMed ID: 7770126
[TBL] [Abstract][Full Text] [Related]
16. Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive.
Dodgshun AJ; Elder JE; Hansford JR; Sullivan MJ
Cancer; 2015 Dec; 121(23):4190-6. PubMed ID: 26280460
[TBL] [Abstract][Full Text] [Related]
17. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Ullrich NJ; Prabhu SP; Packer RJ; Goldman S; Robison NJ; Allen JC; Viskochil DH; Gutmann DH; Perentesis JP; Korf BR; Fisher MJ; Kieran MW;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28833. PubMed ID: 33336845
[TBL] [Abstract][Full Text] [Related]
18. Extensive central nervous system involvement in optic pathway gliomas in neurofibromatosis type 1.
Shaikh F; Johnston D; Michaud J; Hurteau J; Vassilyadi M; Keene D
Pediatr Blood Cancer; 2011 Oct; 57(4):688-6690. PubMed ID: 21465640
[TBL] [Abstract][Full Text] [Related]
19. Optic Pathway Gliomas: The Trends of Basic Research to Reduce the Impact of the Disease on Visual Function.
Bianchi F; Cocilovo FM; Ruggiero A; Tamburrini G
Adv Tech Stand Neurosurg; 2023; 48():123-137. PubMed ID: 37770684
[TBL] [Abstract][Full Text] [Related]
20. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
